Industry Newsendocrinologyclinical trialspalsonifycrinetics pharmaceuticals
Crinetics Gains Analyst Upgrades, Strong Trial Results
|
5.0
Crinetics Pharmaceuticals on Jan. 12 received a Buy upgrade from Goldman Sachs (Richard Law) with a $67 target after trial results showed a 67% reduction in A4 in Cohort 4 and sustained androgen reductions in seven of eight participants despite glucocorticoid dose cuts. Citizens slightly lowered its $105 target while keeping Outperform; analysts cited Palsonify’s positive early experience and preliminary Q4 net product revenue above $5 million.
Scoring Rationale
Moderate investor and clinical relevance from replicated trial data, offset by niche scope and promotional, non-peer-reviewed reporting.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
